T-cell Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Observatory for Patients Treated for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia With Oncogenetic Features.
In order to improve the outcome of relapsed and/or refractory T-cell precursor acute lymphoblastic leukemia (T-ALL) patients, and to facilitate the use of oncogenetic targeted therapies in these patients, we set up an observational cohort, collecting clinical and biological information's from patients with T-ALL in relapse or refractory, as well as the use or not of a targeted therapy. The analysis of the cohort will allow us to evaluate the impact of this therapeutic strategies on the patients' fate, and to facilitate access to innovation and personalized medicine for these patients.
Depending on protocol and leukemia subtype, 5-10% of T-ALL patients are primary refractory, and 30-40% of patients will relapse. A new complete remission is attained in 20-40% of patients, but prolonged disease-free survival is observed in only 10-15% of cases. Nelarabine is approved for R/R T-ALL in second relapses, with a CR rate of 36% in the registration study, and an overall survival of 24% at 1 year and 12% at 3 years. The biological landscape of T-ALL is well characterized, with the identification of at least 10 key recurrently mutated pathways including transcriptional regulation (91% of cases), cell cycle regulation and tumor suppression (84%), NOTCH1 signaling (79%), epigenetic regulation (68%), PI3K-AKT-mTOR signaling (29%), JAK/STAT signaling (25%), RAS signaling (14%), ribosomal function (13%), ubiquitination (9%) and RNA processing (9%). Furthermore, T-ALL cells are dependent upon BCL-XL and upon BCL-2, especially when the T-ALL blasts bear an ETP phenotype. However, genomic data cannot reliably predict the response of leukemic cells to a given treatment, due to interactions of the different cellular pathways affected in a living leukemic cell. Therefore, the combination of genotypic and phenotypic data may overcome this problem. In France, patients with relapsed or refractory T-ALL (and also T-cell lymphoblastic lymphomas) are already proposed to undergo a genotypic (oncogenetic characterization) and a phenotypic (drug testing assay) characterization as a standard of care procedure. Based on the results obtained in fresh leukemic cells, a national scientific committee may recommend the used of targeted drugs alone or in combination, in the context of a "off-label" or a "compassionate" use (for example : Temsirolimus + Erwiniase + Venetoclax in PI3K-AKT-mTOR mutated ALL / Tofacitinib + Venetoclax in IL7R-JAK-STAT mutated ALL / 5-azacytidine + Venetocax in hypermethylated ALL / ...). All patients who undergone this procedure will be proposed to be registered in the ALL-Target registry (ALL-target Observatory). After registration, data related to disease history, disease characterization and disease treatment as well as data describing the patient's condition will be collected. Some patients may receive conventional chemotherapy as a salvage (conventional cohort), others may receive targeted therapy as a salvage (personalized medicine cohort). The aim of the registry is to evaluate the benefit of each treatment strategy in term of response as a primary end point. Comparison between the two cohorts will be performed after adjustment for confounding factors. Results of subgroups will also be reported using descriptive statistics. Secondary endpoints will include safety of the treatment strategy, survival, disease free survival and progression free survival. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05032599 -
Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT06420076 -
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04033302 -
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05995028 -
Universal 4SCAR7U Targeting CD7-positive Malignancies
|
Phase 1 | |
Recruiting |
NCT05596266 -
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
Completed |
NCT01950286 -
Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.
|
N/A | |
Completed |
NCT02518113 -
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
|
Phase 1/Phase 2 | |
Recruiting |
NCT03081910 -
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
|
Phase 1 | |
Recruiting |
NCT05290155 -
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT05289687 -
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
|
Phase 2 | |
Recruiting |
NCT04972942 -
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
|
Phase 1 | |
Recruiting |
NCT06316427 -
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05277753 -
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
|
Phase 1 | |
Not yet recruiting |
NCT06390319 -
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
|
Phase 2 | |
Recruiting |
NCT05679895 -
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
|
Phase 1 | |
Active, not recruiting |
NCT04984356 -
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04860817 -
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
|
Early Phase 1 | |
Recruiting |
NCT04594135 -
Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04934774 -
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
|
Phase 1 | |
Enrolling by invitation |
NCT05509855 -
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
|